Sodium butyrate activates NRF2 to ameliorate diabetic nephropathy possibly via inhibition of HDAC.
J Endocrinol
; 232(1): 71-83, 2017 01.
Article
in En
| MEDLINE
| ID: mdl-27799462
ABSTRACT
Oxidative stress contributes to the pathogenesis of diabetic nephropathy (DN). Nuclear factor erythroid 2-related factor 2 (NRF2) plays a key role in cellular defense against oxidative stress. NRF2 activators have shown promising preventive effects on DN. Sodium butyrate (NaB) is a known activator of NRF2. However, it is unknown whether NRF2 is required for NaB protection against DN. Therefore, streptozotocin-induced diabetic C57BL/6 Nrf2 knockout and their wild-type mice were treated in the presence or absence of NaB for 20 weeks. Diabetic mice, but not NaB-treated diabetic mice, developed significant renal oxidative damage, inflammation, apoptosis, fibrosis, pathological changes and albuminuria. NaB inhibited histone deacetylase (HDAC) activity and elevated the expression of Nrf2 and its downstream targets heme oxygenase 1 and NAD(P)H dehydrogenase quinone 1. Notably, deletion of the Nrf2 gene completely abolished NaB activation of NRF2 signaling and protection against diabetes-induced renal injury. Interestingly, the expression of Kelch-like ECH-associated protein 1, the negative regulator of NRF2, was not altered by NaB under both diabetic and non-diabetic conditions. Moreover, NRF2 nuclear translocation was not promoted by NaB. Therefore, the present study indicates, for the first time, that NRF2 plays a key role in NaB protection against DN. Other findings suggest that NaB may activate Nrf2 at the transcriptional level, possibly by the inhibition of HDAC activity.
Key words
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Butyric Acid
/
Diabetes Mellitus, Experimental
/
Diabetic Nephropathies
/
NF-E2-Related Factor 2
/
Histone Deacetylase Inhibitors
/
Histone Deacetylases
Limits:
Animals
Language:
En
Journal:
J Endocrinol
Year:
2017
Document type:
Article